Huonslab said on Monday that it filed an investigational new drug (IND) application for HLB3-002, a human genetic recombinant hyaluronidase candidate, to Korea's Ministry of Food and Drug Safety.
Huons broke ground on its first overseas manufacturing facility in Vietnam. It is investing a $5.2 million into the medical container plant, which plans to begin production in 2025.
Huons Group has unveiled significant strides in its research and development (R&D) endeavors as it gears up for future expansion.
Huons has taken the initiative in enhancing convenience for diabetes patients, in alignment with the government’s latest health insurance support policies.
Local biomanufacturing and health care company Huons will donate 6,000 glucose monitoring devices to a local community for diabetic patients.
Huons Group is solidifying its global presence as it continues to achieve its highest performance.
Huons is acquiring Crystal Life Sciences from its parent company, CG Invites.
Huons’ Quisqualis Extract Powder, targeting middle-aged men's prostate-related diseases, has become a proven option supported by academic research.
Huons Global saw an on-year surge in its Q3 operating profits, driven by strong growth from subsidiaries Huons, Humedix, and HuM&C.
Huonslab's HLB3-002, a human genetic recombinant hyaluronidase candidate, produced meaningful results confirming its efficacy, the Korean company said Tuesday.
Korea JoongAng Daily Sitemap